Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Relevant Role of Von Willebrand Factor in Ischemia-Reperfusion Model of Acute Kidney Injury in Mice

Shiro Ono, Hideto Matsui, MD PhD, Masashi Noda, Shogo Kasuda, Yasunori Matsunari, MD, Noritaka Yada, Kenji Nishio, Mitsuhiko Sugimoto, MD PhD

Blood (2015) 126 (23): 2243.

https://doi.org/10.1182/blood.V126.23.2243.2243

Published: 2015

Journal Articles

Novel Gene Therapy Strategy for Hemophilia a By Hydrodynamic Gene Delivery Combined with Non-Viral Piggybac Transposon Vector in Canine Model

Masashi Noda, DVM, Hideto Matsui, MD PhD, Yasunori Matsunari, MD, Sunao Ochi, DVM, Midori Shima, MD PhD, Yasushi Fukuoka, Takeshi Sato, MD, Hiroshi Anai, MD PhD, Kimihiko Kichikawa, MD PhD, Masanari Nakayama, DVM, PhD, Akitsu Hotta, PhD, Mitsuhiko Sugimoto, MD PhD

Blood (2015) 126 (23): 4419.

https://doi.org/10.1182/blood.V126.23.4419.4419

Published: 2015

Journal Articles

Von Willebrand Factor-Dependent Inflammatory Responses in Mouse Septic Model By Cecal Ligation and Puncture

Shogo Kasuda, MD, Hideto Matsui, MD, Shiro Ono, MD, Yasunori Matsunari, MD, Kenji Nishio, MD, Midori Shima, MD PhD, Katsuhiko Hatake, MD, Mitsuhiko Sugimoto, MD

Blood (2014) 124 (21): 2773.

https://doi.org/10.1182/blood.V124.21.2773.2773

Published: 2014

Journal Articles

Successful Long-Term Phenotypic Correction Of Hemophilia A Mice By Engineering Functional Factor VIII Delivery System In Vivo Using Autologous Endothelial Cell Sheets

Hideto Matsui, MD, Kohei Tatsumi, MD, Kazuo Ohashi, MD, Midori Shima, MD, Mitsuhiko Sugimoto, MD, Teruo Okano, PhD

Blood (2013) 122 (21): 2899.

https://doi.org/10.1182/blood.V122.21.2899.2899

Published: 2013

Journal Articles

Flow-Dependent Functions Of Soluble Or Immobilized Tissue Factor In Mural Thrombus Formation Mediated By Von Willebrand Factor

Yasunori Matsunari, MD., Masaaki Doi, MD, Hideto Matsui, MD, Kenji Nishio, MD, Hitoshi Furuya, MD, Masahiko Kawaguchi, MD, Mitsuhiko Sugimoto, MD

Blood (2013) 122 (21): 3521.

https://doi.org/10.1182/blood.V122.21.3521.3521

Published: 2013

Journal Articles

ADAMTS13 Improving the Cell Engraftment Efficacy in Mouse Model of Bone Marrow Transplantation

Hideto Matsui, MD, Masaaki Doi, MD, Yasunori Matsunari, MD, Maiko Takeda, MD, Kenji Nishio, MD, Midori Shima, MD, Kenji Soejima, PhD, Fumiaki Banno, PhD, Masashi Akiyama, PhD, Koichi Kokame, PhD, Toshiyuki Miyata, PhD, Mitsuhiko Sugimoto, MD

Blood (2012) 120 (21): 1077.

https://doi.org/10.1182/blood.V120.21.1077.1077

Published: 2012

Journal Articles

Protective Role of ADAMTS13 for Myocardium in Mouse Model of Experimental Myocardial Infarction.

Masaaki Doi, MD, Hideto Matsui, MD, Yukiji Takeda, MD, Yoshihiko Saito, MD, Maiko Takeda, MD, Yasunori Matsunari, MD, Kenji Nishio, MD, Midori Shima, MD, Fumiaki Banno, PhD, Masashi Akiyama, PhD, Koichi Kokame, PhD, Toshiyuki Miyata, PhD, Mitsuhiko Sugimoto, MD

Blood (2012) 120 (21): 2175.

https://doi.org/10.1182/blood.V120.21.2175.2175

Published: 2012

Journal Articles

A Recombinant Thrombomodulin Improves Haemostatic Disturbance and Inflammation in Setpic Patients with DIC

Noritaka Yada, MD, Kenji Nishio, MD, PhD, Hidetada Fukushima, MD, Tadahiko Seki, MD, Yasuyuki Urizono, MD, Michiaki Hata, MD, Hideki Asai, MD, Masaaki Doi, MD, Hideto Matsui, MD, PhD, Mitsuhiko Sugimoto, MD, PhD, Kazuo Okuchi, MD, PhD

Blood (2011) 118 (21): 2293.

https://doi.org/10.1182/blood.V118.21.2293.2293

Published: 2011

Journal Articles

The Ratio of ADAMTS13 to VWF-Propeptide Can Reflect the Disease Severity and the Extent of Inflammation of the Patients with Severe Sepsis or Septic Shock,

Kenji Nishio, MD, PhD, Hidetada Fukushima, MD, Tomoro Watanabe, MD, Tadahiko Seki, MD, Hideto Matsui, MD, PhD, Mitsuhiko Sugimoto, MD, PhD, Masanori Matsumoto, MD, PhD, Yoshihiro Fujimura, MD, PhD, Kazuo Okuchi, MD, PhD

Blood (2011) 118 (21): 3349.

https://doi.org/10.1182/blood.V118.21.3349.3349

Published: 2011

Journal Articles

Critical Role of Immobilized Factor VIII In Solid-Phase Blood Coagulation During Mural Thrombogenesis Under Whole Blood Flow Conditions

Masaaki Doi, MD, Mitsuhiko Sugimoto, MD, PhD, Hideto Matsui, MD, PhD, Tomoko Matsumoto, Midori Shima, MD, PhD

Blood (2010) 116 (21): 2199.

https://doi.org/10.1182/blood.V116.21.2199.2199

Published: 2010

Journal Articles

Immune-Modulatory Effects of Mesenchymal Stromal Cell Infusions for the Treatment of Factor VIII Inhibitor in Hemophilia A.

Hideto Matsui, MD, PhD, Lori Harpell, Sandra Powell, Moutih Rafei, PhD, Jacques Galipeau, MD, Christine Hough, PhD, David Lillicrap, MD

Blood (2009) 114 (22): 1299.

https://doi.org/10.1182/blood.V114.22.1299.1299

Published: 2009

Journal Articles

Genetically-Engineered Endothelial Cells Implanted Into the Omentum of Hemophilia A Dogs Provides Long-Term Circulating FVIII Resulting From Sustained FVIII Expression and Persistent Cell Viability.

Margareth C Ozelo, M.D., Ph.D., Hideto Matsui, MD, PhD, Carol A. Hegadorn, Lori Harpell, Sandra Powell, James F Hulvat, Ph.D., Andrew Winterborn, DVM, DACLAM, Janine Handforth, BSc, (Hons., Biol), DVM, Christine Hough, PhD, David Lillicrap, MD

Blood (2009) 114 (22): 3578.

https://doi.org/10.1182/blood.V114.22.3578.3578

Published: 2009

Journal Articles

Long-Term Phenotypic Correction of Hemophilia A Mice Following Intravenous Injection of miRNA-Regulated Lentiviral Vectors.

Hideto Matsui, MD, PhD, Margareth Ozelo, MD/PhD, Carol Hegadorn, Andrea Labelle, Erin Burnett, Angie Tuttle, Brian Brown, PhD, Luigi Naldini, MD/PhD, Christine Hough, PhD, David Lillicrap, MD

Blood (2007) 110 (11): 2587.

https://doi.org/10.1182/blood.V110.11.2587.2587

Published: 2007

Journal Articles

Ex Vivo Gene Therapy for Haemophilia A: FVIII-Overexpressing Mesenchymal Stromal Cells Fail To Produce Sustained Therapeutic Levels of Circulating FVIII In Vivo .

Daniel L. Coutu, BSc, Moira Francois, Bsc, Jessica Cuerquis, Bsc, Hideto Matsui, MD,PhD, David Lillicrap, MD, Jacques Galipeau, MD

Blood (2006) 108 (11): 5472.

https://doi.org/10.1182/blood.V108.11.5472.5472

Published: 2006

Journal Articles

Ex Vivo Gene Trasfer for Hemophilia A That Enhances Safety and Results in Sustained In Vivo Factor VIII Expression from Lentivirally-Engineered Endothelial Progenitors.

Hideto Matsui, MD, PhD, Masaru Shibata, MD/PhD, Brian Brown, PhD, Andrea Labelle, Carol Hegadorn, Chandler Andrews, Robert P. Hebbel, MD, Jacques Galipeau, MD, Christine Hough, PhD, David Lillicrap, MD

Blood (2006) 108 (11): 3251.

https://doi.org/10.1182/blood.V108.11.3251.3251

Published: 2006

NARROW

Relevant Role of Von Willebrand Factor in Ischemia-Reperfusion Model of Acute Kidney Injury in Mice

Novel Gene Therapy Strategy for Hemophilia a By Hydrodynamic Gene Delivery Combined with Non-Viral Piggybac Transposon Vector in Canine Model

Von Willebrand Factor-Dependent Inflammatory Responses in Mouse Septic Model By Cecal Ligation and Puncture

Successful Long-Term Phenotypic Correction Of Hemophilia A Mice By Engineering Functional Factor VIII Delivery System In Vivo Using Autologous Endothelial Cell Sheets

Flow-Dependent Functions Of Soluble Or Immobilized Tissue Factor In Mural Thrombus Formation Mediated By Von Willebrand Factor

ADAMTS13 Improving the Cell Engraftment Efficacy in Mouse Model of Bone Marrow Transplantation

Protective Role of ADAMTS13 for Myocardium in Mouse Model of Experimental Myocardial Infarction.

A Recombinant Thrombomodulin Improves Haemostatic Disturbance and Inflammation in Setpic Patients with DIC

The Ratio of ADAMTS13 to VWF-Propeptide Can Reflect the Disease Severity and the Extent of Inflammation of the Patients with Severe Sepsis or Septic Shock,

Critical Role of Immobilized Factor VIII In Solid-Phase Blood Coagulation During Mural Thrombogenesis Under Whole Blood Flow Conditions

Immune-Modulatory Effects of Mesenchymal Stromal Cell Infusions for the Treatment of Factor VIII Inhibitor in Hemophilia A.

Genetically-Engineered Endothelial Cells Implanted Into the Omentum of Hemophilia A Dogs Provides Long-Term Circulating FVIII Resulting From Sustained FVIII Expression and Persistent Cell Viability.

Long-Term Phenotypic Correction of Hemophilia A Mice Following Intravenous Injection of miRNA-Regulated Lentiviral Vectors.

Ex Vivo Gene Therapy for Haemophilia A: FVIII-Overexpressing Mesenchymal Stromal Cells Fail To Produce Sustained Therapeutic Levels of Circulating FVIII In Vivo .

Ex Vivo Gene Trasfer for Hemophilia A That Enhances Safety and Results in Sustained In Vivo Factor VIII Expression from Lentivirally-Engineered Endothelial Progenitors.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only